Valiant Helvetique Capital Gain V

95% Swiss stocks, 0.86% TER, and brand new. Valiant's aggressive bet on Switzerland is just getting started.

Valiant Helvetique Capital Gain ranks #65 among 67 3a investment funds in Switzerland. This is the newest and most aggressive fund in Valiant's Swiss-only range, with 95% in domestic stocks. With only one-year data available (+5.46%) and CHF 29 million in assets, it's too early to judge but the early signs are promising.

How Does the Return Stack Up?

The one-year return of +5.46% is a solid start, outperforming many established funds with similar allocations. The 0.86% TER is competitive for a cantonal bank equity product, though still double what digital providers charge. Without three-year or five-year data, any performance assessment is preliminary at best.

The 95% equity allocation means this fund will be volatile. In good years, it should deliver strong returns thanks to the Swiss market's quality companies. In bad years, the lack of bond cushion means drawdowns of 15-25% are entirely possible. That's the trade-off you're accepting.

What Actually Stands Out

This is the only 95% equity Swiss-only 3a fund in the market. If you want maximum domestic equity exposure without any global diversification, Valiant has a monopoly on this specific product. Valiant's track record with Swiss equity management across their broader range provides some confidence in their stock-picking ability.

The Swiss market includes some of the world's best companies: Nestle, Roche, Novartis, Zurich Insurance, ABB, and a deep bench of industrial mid-caps. By concentrating entirely on Swiss equities, you're betting on quality companies in a stable economic environment with the world's strongest currency.

What Most Reviews Miss

CHF 29 million is a critically small fund size. New funds need to attract assets quickly to become economically viable. If Capital Gain doesn't grow significantly in its first 2-3 years, it faces potential closure or merger into Valiant's Dynamic fund. Before investing, ask Valiant about the fund's growth trajectory and minimum viability threshold.

A 95% Swiss-only equity fund is an extreme concentration bet. The top three companies in the SMI represent roughly 50% of the index. You're essentially making a leveraged bet on Swiss pharma and consumer staples. In a global equity downturn specifically hitting these sectors, there's no geographic or sector diversification to protect you.

The Bottom Line

Valiant Helvetique Capital Gain is an interesting new entrant for conviction Swiss equity investors. The 0.86% TER and early return are encouraging, but the fund needs time and assets to prove itself. If you believe deeply in Swiss equity outperformance and want cantonal bank service, put this on your watchlist. Compare it to established options in our Pillar 3a comparison tool.

Verdict: A promising Swiss equity play from Valiant, but too new and too small for most investors. Check back in two years when there's a meaningful track record.